Clinical trials: Dissection of Aorta, Thoracic
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
Expanded access for participants with cancer caused by an abnormal RET gene that did not respond/is no longer responding to treatment with a type of drug called a RET inhibitor.
- Trial name
- NCT05225259
- Testing
- LOXO-260
- Sponsor
- Eli Lilly and Company
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
Extensive-stage Small-cell Lung Cancer
Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study
This is a single-arm, real-world study in Chinese patients with extensive stage small cell lung cancer. The purpose of this study was to evaluate Trilaciclib's protection against chemotherapy-induced bone marrow suppression, the…
- Trial name
- NCT05071703
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Bronchiolo-Alveolar
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
This study will evaluate the safety and efficacy of VELCADE in patients with previously treated stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features.
- Trial name
- NCT00117351
- Testing
- VELCADE
- Where
- United States
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lung Cancer, Pain
Fentanyl Matrix in Lung Cancer Pain
The purpose of this study is to evaluate the usefulness of fentanyl matrix by assessing patients' satisfaction when administrating fentanyl matrix, a background pain treatment, and a breakthrough pain treatment to lung cancer…
- Trial name
- NCT01060137
- Testing
- fentanyl matrix
- Volunteers
- 268 people
- Sponsor
- Janssen Korea, Ltd., Korea
Small Cell Lung Cancer Extensive Stage
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
- Trial name
- NCT06954246
- Testing
- MHB088C for Injection, Topotecan, Irinotecan
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.
This study is to evaluate the preliminary efficacy and safety of Chidamide combined with Envafolimab in patients with PD-1 inhibitor resistant advanced NSCLC.
- Trial name
- NCT05068427
- Testing
- Chidamide, Envafolimab
- Where
- 12 sites in China
- Volunteers
- 34 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Thoracic
MicroCutter in Surgical Stapling - European Trial I
The purpose of this study is to evaluate safety of the Microcutter stapling /cutting device in patients requiring the transection, resection or anastomosis of gastrointestinal tissue in a post-market approval study.
- Trial name
- MET1 (NCT01476761)
- Testing
- Microcutter XPRESS and Microcutter XCHANGE
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- Cardica, Inc
Carcinoma, Non-small-Cell Lung
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
- Trial name
- NCT06116786
- Testing
- JNJ-86974680, Cetrelimab, Radiation Therapy
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 67 people
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC)
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig…
- Conditions
- Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
- Trial name
- NCT05652686
- Testing
- Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel.
- Where
- 15 sites in United States
- Volunteers
- 203 people
- Sponsor
- Phanes Therapeutics
Advanced Solid Tumors, Pancreatic Cancer
Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors
This is a 2-part study to evaluate the safety and antitumor activity of MSC-1. MSC-1 is a first-in-class, humanized monoclonal antibody (IgG1) which binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF)…
- Conditions
- Advanced Solid Tumors, Pancreatic Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
- Trial name
- NCT03490669
- Testing
- MSC-1
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
- Trial name
- NCT05785741
- Testing
- DB-1310, Trastuzumab, Osimertinib
- Where
- 24 sites in United States, China
- Volunteers
- 1,000 people
- Sponsor
- DualityBio Inc.
Non-small Cell Lung Cancer
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
This study was a single-arm, multi-center, prospective, phase 3 trial aimed to evaluate the efficacy and safety of icotinib in patients with locally advanced or metastatic NSCLC after failure of at least one platinum-based…
- Trial name
- NCT02486354
- Testing
- icotinib
- Where
- 10 sites in China
- Volunteers
- 128 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
KRAS P.G12C, Non-small Cell Lung Cancer
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics…
- Conditions
- KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
- Trial name
- NCT05288205
- Testing
- JAB-21822, JAB-3312
- Where
- 27 sites in China
- Volunteers
- 240 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Carcinoma, Non-Small-Cell Lung
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Demonstrate feasibility of detection of EML4-ALK fusion transcripts and T790M EGFR mutation from exosomes in the circulation of Non-Small Cell Lung Cancer (NSCLS) patients.
- Trial name
- NCT03236675
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Lung Cancer
Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand
The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.
- Trial name
- NCT01130961
- Where
- Thailand
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma
Study of Nivolumab for Advanced Cancers in India
This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Kidney Cancer
- Trial name
- NCT03444766
- Testing
- Nivolumab
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
- Trial name
- NCT07229729
- Testing
- SHR-A2102, Adebrelimab, Paclitaxel
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with osimertinib as first-Line treatment for patients with epidermal growth factor receptor (EGFR) mutations, locally advanced or metastatic…
- Trial name
- NCT06670196
- Testing
- SKB264, Osimertinib
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.